Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.

View in: PubMed

subject areas

Antineoplastic Agents
Biopsy
Carcinoma, Renal Cell
Disease Progression
Drug Resistance, Neoplasm
Heterozygote
Humans
In Situ Hybridization, Fluorescence
Kidney Neoplasms
Male
Methionine
Middle Aged
Point Mutation
Proto-Oncogene Proteins c-met
Pyrazines
Receptor Protein-Tyrosine Kinases
Sequence Analysis, DNA
Threonine
Treatment Failure
Triazoles

authors with profiles

Ravi Salgia